Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Declines By 26.8%

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the recipient of a significant decline in short interest in January. As of January 30th, there was short interest totaling 250,987 shares, a decline of 26.8% from the January 15th total of 342,721 shares. Based on an average trading volume of 51,369 shares, the short-interest ratio is currently 4.9 days. Currently, 1.2% of the company’s shares are sold short. Currently, 1.2% of the company’s shares are sold short. Based on an average trading volume of 51,369 shares, the short-interest ratio is currently 4.9 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, ABVC BioPharma currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ABVC. Citadel Advisors LLC purchased a new stake in shares of ABVC BioPharma during the 3rd quarter worth $48,000. Millennium Management LLC bought a new position in ABVC BioPharma in the third quarter worth about $60,000. Finally, Geode Capital Management LLC lifted its position in shares of ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after buying an additional 6,017 shares during the last quarter. 11.38% of the stock is owned by institutional investors.

ABVC BioPharma Stock Performance

NASDAQ ABVC opened at $1.67 on Monday. The company has a market cap of $42.45 million, a PE ratio of -8.35 and a beta of 0.21. The firm’s 50 day moving average price is $2.08 and its 200-day moving average price is $2.60. ABVC BioPharma has a 52-week low of $0.41 and a 52-week high of $5.48.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.